Martina M.D. Flammer Sells 37,828 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Martina M.D. Flammer sold 37,828 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $78.61, for a total transaction of $2,973,659.08. Following the transaction, the insider now owns 100,165 shares of the company's stock, valued at approximately $7,873,970.65. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, February 6th, Martina M.D. Flammer sold 33,055 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50.
• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Stock Up 0.8 %

INSM traded up $0.64 during mid-day trading on Friday, reaching $79.31. 1,167,289 shares of the stock were exchanged, compared to its average volume of 1,950,375. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $14.19 billion, a PE ratio of -14.29 and a beta of 1.11. The company has a 50 day moving average price of $73.38 and a two-hundred day moving average price of $73.28. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $82.04.

Analysts Set New Price Targets

Several analysts have recently weighed in on INSM shares. Truist Financial reiterated a "buy" rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Guggenheim lifted their price objective on shares of Insmed from $95.00 to $101.00 and gave the company a "buy" rating in a research note on Friday, February 7th. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Finally, Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.71.

Hedge Funds Weigh In On Insmed

A number of hedge funds have recently bought and sold shares of the company. National Bank of Canada FI boosted its holdings in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 147 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company's stock worth $324,000 after acquiring an additional 149 shares during the last quarter. Abel Hall LLC boosted its holdings in Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock worth $230,000 after acquiring an additional 151 shares during the last quarter. Commerce Bank boosted its holdings in Insmed by 2.4% during the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 163 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.